Literature DB >> 6770884

Time dependence of the in vitro cytotoxicity of hexamethylmelamine and its metabolites.

M D'Incalci, E Erba, G Balconi, L Morasca, S Garattini.   

Abstract

The cytotoxicity of hexamethylmelamine (HMM) and its metabolites pentamethylmelamine (PMM), N,2,2,4,6-tetramethylmelamine (TMM) and hydroxymethylpentamethylmelamine (HMPMM) and of the alkylating agent triethylenemelamine (TEM) were studied on a cell line derived from a human ovarian cancer, by measuring [3H]TdR uptake. After 24 h of incubation all the tested compounds inhibited [3H]TdR uptake, but only at a concentration of 100 micrograms/ml. However, after 120 h incubation, concentrations of 0.1--10 micrograms/ml resulted in highly significant cytotoxicity. HMPMM and TEM were the most active and their effect was not reversed 72 h after their removal. In our in vitro system no metabolism of HMM was observed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6770884      PMCID: PMC2010283          DOI: 10.1038/bjc.1980.106

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Effect of hexamethylmelamine (NSC-13875) on small cell carcinoma of the lung (phase II study).

Authors:  H Takita; M S Didolkar
Journal:  Cancer Chemother Rep       Date:  1974 May-Jun

2.  Hexamethylmelamine--a new drug with activity in solid tumors.

Authors:  R H Blum; R B Livingston; S K Carter
Journal:  Eur J Cancer       Date:  1973-03       Impact factor: 9.162

3.  Metabolism of hexamethylmelamine-ring-14C in rats and man.

Authors:  J F Worzalla; B D Kaiman; B M Johnson; G Ramirez; G T Bryan
Journal:  Cancer Res       Date:  1974-10       Impact factor: 12.701

4.  In vitro studies with hexamethylmelamine.

Authors:  C J Rutty; T A Connors
Journal:  Biochem Pharmacol       Date:  1977-12-15       Impact factor: 5.858

5.  N-demethylation of the antineoplastic agent hexamethylmelamine by rats and man.

Authors:  J F Worzalla; B M Johnson; G Ramirez; G T Bryan
Journal:  Cancer Res       Date:  1973-11       Impact factor: 12.701

6.  Plasma levels and urinary excretion of hexamethylmelamine following oral administration to human subjects with cancer.

Authors:  G T Bryan; J F Worzalla; A L Gorske; G Ramirez
Journal:  Clin Pharmacol Ther       Date:  1968 Nov-Dec       Impact factor: 6.875

7.  Insect chemosterilants. VII. Oxidative degradation of hexamethylmelamine.

Authors:  A B DeMilo; A B Borkovec
Journal:  J Med Chem       Date:  1968-09       Impact factor: 7.446

8.  Phase II study of hexamethylmelamine (NSC 13875).

Authors:  W L Wilson; J M Schroeder; H F Bisel; R Mrazek; R P Hummel
Journal:  Cancer       Date:  1969-01       Impact factor: 6.860

9.  Hexamethylmelamine. An evaluation of its role in the therapy of cancer.

Authors:  S S Legha; M Slavik; S K Carter
Journal:  Cancer       Date:  1976-07       Impact factor: 6.860

10.  Toxicity and antitumor activity of hexamethylmelamine and its N-demethylated metabolites in mice with transplantable tumors.

Authors:  L M Lake; E E Grunden; B M Johnson
Journal:  Cancer Res       Date:  1975-10       Impact factor: 12.701

View more
  6 in total

1.  Pharmacokinetics and metabolism of hexamethylmelamine in mice after IP administration.

Authors:  J Dubois; G Atassi; M Hanocq; F Abikhalil
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 2.  Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.

Authors:  C R Lee; D Faulds
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 3.  N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors:  D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Pharmacokinetics and metabolism of hexamethylmelamine in mice bearing renal cell tumors.

Authors:  J Dubois; G Atassi; M Hanocq; F Abikhalil
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 5.  Clinical pharmacokinetics of altretamine.

Authors:  G Damia; M D'Incalci
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

6.  Clinical correlates of in vitro drug sensitivities of ovarian cancer cells.

Authors:  L Morasca; E Erba; M Vaghi; C Ghelardoni; C Mangioni; C Sessa; F Landoni; S Garattini
Journal:  Br J Cancer       Date:  1983-07       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.